Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Lung Neoplasms
  • Proto-Oncogene Proteins
  • Receptor, Epidermal Growth Factor
  • ras Proteins

abstract

  • Cytologic subtyping of NSCLC is feasible and accurate, particularly when morphologic assessment is combined with IHC. Furthermore, routine cytologic specimens can be successfully used for EGFR/KRAS mutation analysis. Our data strongly support the suitability of cytologic specimens for the new therapeutic paradigms in NSCLC.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e31820517a3

PubMed ID

  • 21266922

Additional Document Info

start page

  • 451

end page

  • 8

volume

  • 6

number

  • 3